Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women

PURPOSE: To evaluate the cost-effectiveness of adding ribociclib to endocrine therapy for pre/perimenopausal women with hormone receptor-positive (HR+), human epidermal receptor 2-negative (HER2-) advanced breast cancer from the US payer perspective. METHODS: A partitioned survival analysis model wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Eunae, Wang, Changjun, Wilson, Leslie, Zhong, Lixian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138037/
https://www.ncbi.nlm.nih.gov/pubmed/34026637
http://dx.doi.org/10.3389/fonc.2021.658054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138037/
https://www.ncbi.nlm.nih.gov/pubmed/34026637
http://dx.doi.org/10.3389/fonc.2021.658054

Ejemplares similares